<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063800</url>
  </required_header>
  <id_info>
    <org_study_id>PREBOP (29BRC18.0108)</org_study_id>
    <nct_id>NCT04063800</nct_id>
  </id_info>
  <brief_title>Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI</brief_title>
  <acronym>PREBOP</acronym>
  <official_title>Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With 50% of post-operative biochemical failure, efficient predictive models are needed to
      guide post-operative management.

      Radiomic features are quantitative features extracted from medical imaging, supposed to be
      correlated with tumor heterogeneity.

      We aim to build and test three predictive models (clinical, radiomic and combined models).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">August 28, 2018</completion_date>
  <primary_completion_date type="Actual">August 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of biochemical failure</measure>
    <time_frame>From the date of surgery until data collection (up to 100 months)</time_frame>
    <description>Comparison of AUCs between each predictive model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of survival without biochemical failure</measure>
    <time_frame>From the date of surgery until data collection (up to 100 months)</time_frame>
    <description>Survival analysis: comparison of Kaplan-Meier curves</description>
  </secondary_outcome>
  <enrollment type="Actual">195</enrollment>
  <condition>Prostatic Adenocarcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        - Patients with high-risk prostate cancers who underwent pre-operative prostate MRI
        followed by radical prostatectomy +/- lymphadenectomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18yo

          -  Patients underwent radical prostatectomy

          -  High-risk prostate cancers: at least 1 criteria (pt3a/pT3b/pT4, R1, Gleason score &gt; 7)

        Exclusion Criteria:

          -  No available pre-operative MRI

          -  No analyzable pre-operative MRI

          -  proof of lymph-node involvement (cN1/2 or pN1/2)

          -  post-operative PSA &gt; 0.04ng/mL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <state>Bretagne</state>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning one year and ending following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

